SG Americas Securities LLC Acquires 617,629 Shares of Roivant Sciences Ltd. $ROIV

SG Americas Securities LLC boosted its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) by 2,651.5% during the first quarter, Holdings Channel.com reports. The fund owned 640,923 shares of the company’s stock after buying an additional 617,629 shares during the quarter. SG Americas Securities LLC’s holdings in Roivant Sciences were worth $17,754,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. TD Asset Management Inc increased its position in shares of Roivant Sciences by 94.7% in the third quarter. TD Asset Management Inc now owns 316,200 shares of the company’s stock worth $4,784,000 after purchasing an additional 153,800 shares during the last quarter. Fox Run Management L.L.C. bought a new stake in Roivant Sciences during the third quarter valued at approximately $877,000. HighVista Strategies LLC grew its stake in Roivant Sciences by 61.4% in the 3rd quarter. HighVista Strategies LLC now owns 98,858 shares of the company’s stock worth $1,496,000 after buying an additional 37,590 shares in the last quarter. Pictet Asset Management Holding SA grew its stake in Roivant Sciences by 790.3% in the 4th quarter. Pictet Asset Management Holding SA now owns 2,312,436 shares of the company’s stock worth $50,180,000 after buying an additional 2,052,693 shares in the last quarter. Finally, Neo Ivy Capital Management increased its holdings in shares of Roivant Sciences by 229.6% in the 3rd quarter. Neo Ivy Capital Management now owns 237,392 shares of the company’s stock worth $3,592,000 after buying an additional 165,362 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Stock Performance

ROIV stock opened at $34.02 on Friday. The company has a market capitalization of $24.47 billion, a PE ratio of -56.70 and a beta of 1.13. Roivant Sciences Ltd. has a one year low of $10.70 and a one year high of $34.68. The company’s 50 day moving average price is $29.57 and its two-hundred day moving average price is $26.72.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Wednesday, May 20th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.57. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. The firm had revenue of $2.52 million during the quarter, compared to analyst estimates of $3.41 million. During the same period in the previous year, the business posted ($0.29) EPS. On average, research analysts predict that Roivant Sciences Ltd. will post -1.83 EPS for the current year.

Insider Buying and Selling

In other news, CEO Matthew Gline sold 289,774 shares of the firm’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $29.16, for a total transaction of $8,449,809.84. Following the transaction, the chief executive officer directly owned 16,736,116 shares of the company’s stock, valued at approximately $488,025,142.56. This trade represents a 1.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Jennifer Humes sold 13,538 shares of the firm’s stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $28.37, for a total value of $384,073.06. Following the transaction, the chief accounting officer directly owned 84,191 shares in the company, valued at $2,388,498.67. This trade represents a 13.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 703,312 shares of company stock worth $20,805,883 in the last 90 days. 10.80% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ROIV. Leerink Partners set a $42.00 price objective on shares of Roivant Sciences in a research report on Thursday, May 21st. TD Cowen upped their target price on shares of Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a research report on Thursday, May 21st. Weiss Ratings cut Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Citigroup raised their price target on Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, May 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $34.00 price target on shares of Roivant Sciences in a research note on Thursday, May 21st. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.59.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.